Pixium Vision SA
PAR:ALPIX
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
N/A
N/A
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Pixium Vision SA
Pixium Vision SA conducts research and development on retinal implants. The company is headquartered in Paris, Ile-De-France. The company went IPO on 2014-06-19. The firm is focused on the development of implantable medical devices for the treatment of blindness caused by degeneration of photoreceptor cells in the retina. The firm develops two Vision Restoration Systems (VRS) platforms, including IRIS and PRIMA. The Company’s implant technology replaces the signal processing functions in the retina by electrically stimulating the retinal cells, enabling them to transmit the stimulation signals to the brain’s visual cortex via the optic nerve, and its other systems initially enables patients with retinitis pigmentosa to partially recover their vision. The firm has collaboration with technology and academic institutions, including the Institut de la Vision (Paris), Universite Pierre et Marie Curie (Paris), Stanford University (the United States) and University of Ulm (Germany).
Pixium Vision SA conducts research and development on retinal implants. The company is headquartered in Paris, Ile-De-France. The company went IPO on 2014-06-19. The firm is focused on the development of implantable medical devices for the treatment of blindness caused by degeneration of photoreceptor cells in the retina. The firm develops two Vision Restoration Systems (VRS) platforms, including IRIS and PRIMA. The Company’s implant technology replaces the signal processing functions in the retina by electrically stimulating the retinal cells, enabling them to transmit the stimulation signals to the brain’s visual cortex via the optic nerve, and its other systems initially enables patients with retinitis pigmentosa to partially recover their vision. The firm has collaboration with technology and academic institutions, including the Institut de la Vision (Paris), Universite Pierre et Marie Curie (Paris), Stanford University (the United States) and University of Ulm (Germany).